Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARI-STEP: Semaglutide in Patients With Poor Weight-loss Following Bariatric Surgery
NCT05073835Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2022
- Primary completion
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity (2 arms), sponsored by University College London. Primary endpoint: Percentage Weight Change at 68 weeks. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05073835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05073835.